Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.


Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
14 11 2022
Historique:
received: 12 08 2021
revised: 21 03 2022
accepted: 20 07 2022
pubmed: 19 8 2022
medline: 18 11 2022
entrez: 18 8 2022
Statut: ppublish

Résumé

Genetic predisposition is has been identified as a cause of cancer, yet little is known about the role of adult cancer predisposition syndromes in childhood cancer. We examined the extent to which heterozygous pathogenic germline variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, MSH2, MSH6, MLH1, and PMS2 contribute to cancer risk in children and adolescents. We conducted a meta-analysis of 11 studies that incorporated comprehensive germline testing for children and adolescents with cancer. ClinVar pathogenic or likely pathogenic variants (PVs) in genes of interest were compared with 2 control groups. Results were validated in a cohort of mainly European patients and controls. We employed the Proxy External Controls Association Test to account for different pipelines. Among 3975 children and adolescents with cancer, statistically significant associations with cancer risk were observed for PVs in BRCA1 and 2 (26 PVs vs 63 PVs among 27 501 controls, odds ratio = 2.78, 95% confidence interval = 1.69 to 4.45; P < .001) and mismatch repair genes (19 PVs vs 14 PVs among 27 501 controls, odds ratio = 7.33, 95% confidence interval = 3.64 to 14.82; P <.001). Associations were seen in brain and other solid tumors but not in hematologic neoplasms. We confirmed similar findings in 1664 pediatric cancer patients primarily of European descent. These data suggest that heterozygous PVs in BRCA1 and 2 and mismatch repair genes contribute with reduced penetrance to cancer risk in children and adolescents. No changes to predictive genetic testing and surveillance recommendations are required.

Sections du résumé

BACKGROUND
Genetic predisposition is has been identified as a cause of cancer, yet little is known about the role of adult cancer predisposition syndromes in childhood cancer. We examined the extent to which heterozygous pathogenic germline variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, MSH2, MSH6, MLH1, and PMS2 contribute to cancer risk in children and adolescents.
METHODS
We conducted a meta-analysis of 11 studies that incorporated comprehensive germline testing for children and adolescents with cancer. ClinVar pathogenic or likely pathogenic variants (PVs) in genes of interest were compared with 2 control groups. Results were validated in a cohort of mainly European patients and controls. We employed the Proxy External Controls Association Test to account for different pipelines.
RESULTS
Among 3975 children and adolescents with cancer, statistically significant associations with cancer risk were observed for PVs in BRCA1 and 2 (26 PVs vs 63 PVs among 27 501 controls, odds ratio = 2.78, 95% confidence interval = 1.69 to 4.45; P < .001) and mismatch repair genes (19 PVs vs 14 PVs among 27 501 controls, odds ratio = 7.33, 95% confidence interval = 3.64 to 14.82; P <.001). Associations were seen in brain and other solid tumors but not in hematologic neoplasms. We confirmed similar findings in 1664 pediatric cancer patients primarily of European descent.
CONCLUSION
These data suggest that heterozygous PVs in BRCA1 and 2 and mismatch repair genes contribute with reduced penetrance to cancer risk in children and adolescents. No changes to predictive genetic testing and surveillance recommendations are required.

Identifiants

pubmed: 35980168
pii: 6671221
doi: 10.1093/jnci/djac151
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 protein, human 0
BRCA2 Protein 0

Types de publication

Meta-Analysis Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1523-1532

Subventions

Organisme : CIHR
ID : FDN-143234
Pays : Canada

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press.

Auteurs

Christian P Kratz (CP)

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Dmitrii Smirnov (D)

Institute of Human Genetics, School of Medicine, Technische Universität München, München, Germany.
Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany.

Robert Autry (R)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Natalie Jäger (N)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.

Sebastian M Waszak (SM)

Centre for Molecular Medicine Norway (NCMM), Nordic European Molecular Biology Laboratory (EMBL) Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Anika Großhennig (A)

Institute of Biostatistics, Hannover Medical School, Hannover, Germany.

Riccardo Berutti (R)

Institute of Human Genetics, School of Medicine, Technische Universität München, München, Germany.
Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany.

Mareike Wendorff (M)

Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.

Pierre Hainaut (P)

Univ. Grenoble Alpes, Inserm 1209, CNRS 5309, Institute for Advanced Biosciences, F38000, Grenoble, France.

Stefan M Pfister (SM)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Holger Prokisch (H)

Institute of Human Genetics, School of Medicine, Technische Universität München, München, Germany.
Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany.

Tim Ripperger (T)

Department of Human Genetics, Hannover Medical School, Hannover, Germany.

David Malkin (D)

Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.
Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Paediatrics, University of Toronto, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH